AGREEMENT TO FILE JOINT SCHEDULE 13DAgreement to File Joint Schedule 13d • February 12th, 2018 • Stetson John • Pharmaceutical preparations
Contract Type FiledFebruary 12th, 2018 Company IndustryPursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13D and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of shares of the common stock of MabVax Therapeutics, Holdings, Inc., a Delaware corporation. The undersigned hereby further agree that this statement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.
AGREEMENT TO FILE JOINT SCHEDULE 13DAgreement to File Joint Schedule 13d • October 9th, 2018 • Stetson John • Biological products, (no disgnostic substances)
Contract Type FiledOctober 9th, 2018 Company IndustryPursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13D and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of shares of the common stock of PolarityTE, Inc., a Delaware corporation. The undersigned hereby further agree that this statement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.
AGREEMENT TO FILE JOINT SCHEDULE 13DAgreement to File Joint Schedule 13d • July 25th, 2018 • Stetson John • Pharmaceutical preparations
Contract Type FiledJuly 25th, 2018 Company IndustryPursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13D and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of shares of the common stock of MabVax Therapeutics Holdings, Inc., a Delaware corporation. The undersigned hereby further agree that this statement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.
AGREEMENT TO FILE JOINT SCHEDULE 13GAgreement to File Joint Schedule 13g • February 12th, 2019 • Stetson John • Pharmaceutical preparations
Contract Type FiledFebruary 12th, 2019 Company IndustryPursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13G and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of American Depositary Shares of Therapix Biosciences Ltd. The undersigned hereby further agree that this statement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.
AGREEMENT TO FILE JOINT SCHEDULE 13DAgreement to File Joint Schedule 13d • February 13th, 2018 • Stetson John • Services-prepackaged software
Contract Type FiledFebruary 13th, 2018 Company IndustryPursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby consent to the joint filing on their behalf of a single Schedule 13D and any amendments thereto, with respect to the beneficial ownership by each of the undersigned of shares of the common stock of PolarityTE, Inc., a Delaware corporation. The undersigned hereby further agree that this statement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.